Idursulfase for the treatment of mucopolysaccharidosis II
- 17 January 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 9 (2) , 311-317
Abstract
Human recombinant proteins are being used to treat an increasing number of disorders. Advances in the large scale production of recombinant proteins and the understanding of glycosylation and its importance for protein targeting and function have led to the development of recombinant enzyme-replacement regimens for a number of human lysosomal storage diseases. The latest addition to this group is mucopolysaccharidosis II or Hunter syndrome. Purified human recombinant idursulfase has been shown to alter disease manifestations in individuals with Hunter syndrome. The recent approval in the US, Europe, Canada and Japan of idursulfase for the treatment of Hunter syndrome introduces the first pharmacologic agent and indeed the first specific treatment directed towards this devastating genetic disease.Keywords
This publication has 26 references indexed in Scilit:
- A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Genetics in Medicine, 2006
- Analysis of normal and mutant iduronate-2-sulphatase conformationBiochemical Journal, 2005
- Incidence of the mucopolysaccharidoses in Western AustraliaAmerican Journal of Medical Genetics Part A, 2003
- Long‐term follow‐up following bone marrow transplantation for Hunter diseaseJournal of Inherited Metabolic Disease, 1999
- Prevalence of Lysosomal Storage DisordersJAMA, 1999
- Incidence of the mucopolysaccharidoses in Northern IrelandHuman Genetics, 1997
- Bone marrow transplantation in Hunter syndromeThe Journal of Pediatrics, 1996
- Lysosomal Degradation of Heparin and Heparan Sulphate1992
- An update on the frequency of mucopolysaccharide syndromes in British ColumbiaHuman Genetics, 1990
- Characterization of a newly derived human sarcoma cell line (HT-1080)Cancer, 1974